Introduction Five conditions account for 80% of deaths related to chronic non-communicable diseases, with diabetes mellitus (DM) being one of the leading contributors ( A treatment strategy based on stricter glucose control, intended to reduce glycated hemoglobin (HbA1c) levels to close to those of a person without diabetes, has been shown to reduce mortality and the appearance of micro- and macrovascular complications in people with DM ( The landscape of T2D treatment has evolved, and current recommendations emphasize not only glycemic control but also reducing the risk of conditions such as cardiovascular disease and kidney disease, aiding weight loss in people with obesity, and promoting a patient-centered approach ( The once-weekly subcutaneous glucagon-like peptide-1 receptor agonist (GLP1-RA), semaglutide (OWS), has shown superior efficacy in glycemic control and weight loss compared to placebo and multiple comparators, as demonstrated by the SUSTAIN clinical trial program ( The SURE program complemented the data from the SUSTAIN clinical trials as it investigated OWS in a real-world setting in several European countries ( Diabetes treatment in Latin American countries differs significantly from that provided in Europe and North America, a distinction influenced by cultural, social, economic, and genetic factors, as well as healthcare coverage
Mais ces effets secondaires bnins ne doivent pas en occulter d'autres, eux plus rares mais bien plus svres
After all, like Mounjaro and Saxenda weight loss injections, you insert it into the fatty tissue under your skin
Owczarek W, Slowinska M, Walecka I, Ciazynska M, Nowicka D, Walczak L, et al
Clinical trials often reveal a pattern of quick initial weight loss that eventually levels off
